Gary Lyons Sells 8,000 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) Director Gary Lyons sold 8,000 shares of Travere Therapeutics stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $41.07, for a total transaction of $328,560.00. Following the completion of the transaction, the director owned 57,500 shares in the company, valued at approximately $2,361,525. This trade represents a 12.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Trading Up 3.1%

Travere Therapeutics stock opened at $40.77 on Friday. The company has a debt-to-equity ratio of 2.71, a quick ratio of 2.70 and a current ratio of 2.74. The firm has a market cap of $3.77 billion, a price-to-earnings ratio of -135.90 and a beta of 0.86. Travere Therapeutics, Inc. has a 1 year low of $13.88 and a 1 year high of $43.31. The firm’s 50 day moving average price is $29.99 and its two-hundred day moving average price is $31.54.

Hedge Funds Weigh In On Travere Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TVTX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Travere Therapeutics by 13.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,777 shares of the company’s stock worth $1,029,000 after purchasing an additional 6,831 shares during the period. Norges Bank acquired a new position in Travere Therapeutics in the 2nd quarter worth approximately $1,051,000. First Trust Advisors LP acquired a new position in Travere Therapeutics in the 2nd quarter worth approximately $3,538,000. Cresset Asset Management LLC boosted its stake in Travere Therapeutics by 26.5% in the 2nd quarter. Cresset Asset Management LLC now owns 28,875 shares of the company’s stock worth $427,000 after purchasing an additional 6,047 shares during the period. Finally, Qube Research & Technologies Ltd boosted its stake in Travere Therapeutics by 106.2% in the 2nd quarter. Qube Research & Technologies Ltd now owns 604,128 shares of the company’s stock worth $8,941,000 after purchasing an additional 311,137 shares during the period.

Travere Therapeutics News Summary

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: FDA grants full approval for Filspari in focal segmental glomerulosclerosis (FSGS), expanding Travere’s addressable U.S. patient population and underpinning multi‑year revenue upside. Filspari approval article
• Positive Sentiment: Multiple brokerages raised ratings and price targets (examples cited include Canaccord, Guggenheim, Piper Sandler and HC Wainwright), reinforcing bullish revenue and valuation revisions tied to the approval. Guggenheim note
• Neutral Sentiment: Trading and options volumes are unusually high around the approval-driven move, amplifying short‑term swings and making intraday price moves less predictive of fundamentals. Options activity report
• Neutral Sentiment: Company commentary and analyst write‑ups are clarifying label scope and launch plans but have not yet produced concrete revenue reads — useful for modeling but not definitive for near‑term earnings. Company discussion
• Negative Sentiment: Significant insider selling occurred over the last two trading days (CEO, directors, CFO, CAO and others). Most sales were via Rule 10b5‑1 plans or to cover tax withholding, but the scale of disposals can intensify near‑term downward pressure and signal profit‑taking after the approval rally. Insider trades summary
• Negative Sentiment: Some analysts caution that elevated expectations and rapid estimate revisions may limit further upside near term; the stock could consolidate or retrace as investors re‑rate forward revenue assumptions. Zacks caution

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Canaccord Genuity Group lifted their price target on shares of Travere Therapeutics from $47.00 to $56.00 and gave the stock a “buy” rating in a research report on Tuesday. Guggenheim lifted their price target on shares of Travere Therapeutics from $49.00 to $54.00 and gave the stock a “buy” rating in a research report on Tuesday. Weiss Ratings restated a “sell (e+)” rating on shares of Travere Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen lowered shares of Travere Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 21st. Finally, Citigroup lifted their price target on shares of Travere Therapeutics from $48.00 to $53.00 and gave the stock a “buy” rating in a research report on Tuesday. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.50.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.